These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18664955)

  • 1. Universal access to HIV treatment in developing countries: going beyond the misinterpretations of the 'cost-effectiveness' algorithm.
    Moatti JP; Marlink R; Luchini S; Kazatchkine M
    AIDS; 2008 Jul; 22 Suppl 1():S59-66. PubMed ID: 18664955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs associated with combination antiretroviral therapy in HIV-infected patients.
    Yazdanpanah Y
    J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing resource allocation for HIV/AIDS prevention programmes: an analytical framework.
    Bautista-Arredondo S; Gadsden P; Harris JE; Bertozzi SM
    AIDS; 2008 Jul; 22 Suppl 1():S67-74. PubMed ID: 18664956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
    Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
    AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
    Mrus JM; Tsevat J
    Med Decis Making; 2004; 24(1):30-9. PubMed ID: 15005952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa.
    Boulle A; Kenyon C; Skordis J; Wood R
    S Afr Med J; 2002 Oct; 92(10):811-7. PubMed ID: 12432807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
    Bishai D; Colchero A; Durack DT
    AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How can we calculate the "E" in "CEA"?
    Bollinger LA
    AIDS; 2008 Jul; 22 Suppl 1():S51-7. PubMed ID: 18664954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing efficiency and costs of scaling up HIV treatment.
    Cleary SM; McIntyre D; Boulle AM
    AIDS; 2008 Jul; 22 Suppl 1():S35-42. PubMed ID: 18664951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equity and efficiency in HIV-treatment in South Africa: the contribution of mathematical programming to priority setting.
    Cleary S; Mooney G; McIntyre D
    Health Econ; 2010 Oct; 19(10):1166-80. PubMed ID: 19725025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi.
    Renaud A; Basenya O; de Borman N; Greindl I; Meyer-Rath G
    AIDS Care; 2009 Nov; 21(11):1388-94. PubMed ID: 20024715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
    PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic impact of HIV.
    Veenstra N; Whiteside A
    Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):197-210. PubMed ID: 15778110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Socioeconomic aspects of human immunodeficiency virus (HIV) infection in developing countries].
    Gentilini M; Chieze F
    Bull Acad Natl Med; 1990 Nov; 174(8):1209-19; discussion 1219-21. PubMed ID: 2094555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of cervical-cancer screening in five developing countries.
    Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
    N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The affordability of antiretroviral therapy in developing countries: what policymakers need to know.
    Forsythe SS
    AIDS; 1998; 12 Suppl 2():S11-8. PubMed ID: 9792357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
    Marseille E; Saba J; Muyingo S; Kahn JG
    AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.